Join our daily newsletter At The Bell to receive exclusive market insights
- OncoSil Medical (OSL) gains ethics committee approval for its PANCOSIL trial, focused on treating patients with locally advanced pancreatic cancer (LAPC)
- The company will recruit 15 patients for treatment using its OncoSil device via a percutaneous application
- The study is aimed to develop a new standardised approach that will be the basis for gaining approval in Europe and the UK
- The investigator-initiated trial is being led by Professor Marc Besselink of Amsterdam UMC, a leading Hepato-Pancreato-Biliary surgeon in Europe
- OSL shares last traded at 1.2 cents
OncoSil Medical (OSL) has gained ethics committee approval for its PANCOSIL trial, focused on treating patients with locally advanced pancreatic cancer (LAPC).
The company announced it would recruit up to 15 patients for treatment using its OncoSil device, inserted percutaneously through the skin directly into pancreatic tumours under CT guidance.
The investigator-initiated trial is being spearheaded by a leading Hepato-Pancreato-Biliary surgeon in Europe, Professor Marc Besselink from Amsterdam UMC.
“I am excited to be part of an innovative clinical trial in developing the percutaneous application of the OncoSil device for patients with locally advanced pancreatic cancer, who have stable disease after several months of chemotherapy,” he said.
OSL also announced it would provide the doses at no cost for the trial.
The study is expected to develop a new standardised approach that will be the basis for gaining approval in Europe and the UK, and ultimately lead to greater use of the OncoSil device upon larger groups of patients.
OSL shares last traded at 1.2 cents.
